| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetic Therapy | 10 | 2025 | 711 | 1.810 |
Why?
|
| T-Lymphocytes | 23 | 2026 | 1707 | 1.490 |
Why?
|
| Cell- and Tissue-Based Therapy | 6 | 2025 | 150 | 1.420 |
Why?
|
| Immunotherapy, Adoptive | 16 | 2026 | 950 | 1.360 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 10 | 2023 | 1273 | 0.680 |
Why?
|
| Anemia, Sickle Cell | 1 | 2025 | 332 | 0.660 |
Why?
|
| Receptors, Antigen, T-Cell | 8 | 2025 | 499 | 0.650 |
Why?
|
| Neuroblastoma | 5 | 2025 | 547 | 0.430 |
Why?
|
| Herpesvirus 4, Human | 8 | 2025 | 639 | 0.410 |
Why?
|
| Gangliosides | 2 | 2025 | 72 | 0.410 |
Why?
|
| Antigens, Neoplasm | 4 | 2026 | 393 | 0.400 |
Why?
|
| Hodgkin Disease | 4 | 2020 | 306 | 0.390 |
Why?
|
| Graft vs Host Disease | 6 | 2022 | 688 | 0.370 |
Why?
|
| Oncolytic Viruses | 2 | 2024 | 84 | 0.370 |
Why?
|
| Tissue and Organ Procurement | 1 | 2015 | 253 | 0.360 |
Why?
|
| Lymphoma | 3 | 2023 | 327 | 0.360 |
Why?
|
| Lymphoma, T-Cell | 2 | 2024 | 60 | 0.340 |
Why?
|
| Stem Cells | 1 | 2015 | 703 | 0.320 |
Why?
|
| Health Services Accessibility | 3 | 2025 | 698 | 0.320 |
Why?
|
| Antigens, CD19 | 5 | 2024 | 189 | 0.310 |
Why?
|
| Salvage Therapy | 3 | 2021 | 174 | 0.310 |
Why?
|
| United States Food and Drug Administration | 3 | 2025 | 155 | 0.300 |
Why?
|
| Caspase 9 | 3 | 2015 | 76 | 0.300 |
Why?
|
| Ki-1 Antigen | 2 | 2020 | 31 | 0.290 |
Why?
|
| Pancreatic Neoplasms | 2 | 2026 | 735 | 0.280 |
Why?
|
| Drugs, Investigational | 2 | 2023 | 27 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2024 | 1265 | 0.270 |
Why?
|
| Sarcoma | 2 | 2024 | 218 | 0.260 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2018 | 163 | 0.250 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2016 | 175 | 0.250 |
Why?
|
| Retroviridae | 4 | 2022 | 182 | 0.240 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2013 | 510 | 0.240 |
Why?
|
| Humans | 46 | 2026 | 130075 | 0.230 |
Why?
|
| Hematologic Neoplasms | 2 | 2022 | 314 | 0.220 |
Why?
|
| Glypicans | 1 | 2024 | 36 | 0.210 |
Why?
|
| Leukemia | 3 | 2022 | 375 | 0.210 |
Why?
|
| Neoplasms | 3 | 2024 | 2977 | 0.210 |
Why?
|
| Interleukin-15 | 1 | 2024 | 104 | 0.200 |
Why?
|
| Marketing | 1 | 2023 | 8 | 0.200 |
Why?
|
| Lymphoma, B-Cell | 2 | 2018 | 145 | 0.200 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2026 | 191 | 0.200 |
Why?
|
| Neomycin | 2 | 2000 | 36 | 0.200 |
Why?
|
| Compassionate Use Trials | 1 | 2023 | 17 | 0.200 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2018 | 289 | 0.200 |
Why?
|
| Interleukin-2 | 4 | 2005 | 235 | 0.190 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 220 | 0.180 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2021 | 125 | 0.180 |
Why?
|
| United States | 4 | 2025 | 11893 | 0.180 |
Why?
|
| Natural Killer T-Cells | 1 | 2023 | 91 | 0.180 |
Why?
|
| Transplantation, Homologous | 7 | 2022 | 668 | 0.180 |
Why?
|
| Oncolytic Virotherapy | 1 | 2023 | 106 | 0.170 |
Why?
|
| Treatment Outcome | 15 | 2026 | 12819 | 0.170 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2024 | 211 | 0.170 |
Why?
|
| Lymphocyte Transfusion | 1 | 2021 | 55 | 0.170 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2021 | 39 | 0.170 |
Why?
|
| Muscle Neoplasms | 1 | 2020 | 21 | 0.160 |
Why?
|
| Recurrence | 7 | 2022 | 1475 | 0.160 |
Why?
|
| Male | 28 | 2026 | 64382 | 0.160 |
Why?
|
| Anemia | 1 | 2024 | 352 | 0.160 |
Why?
|
| Child | 17 | 2025 | 26168 | 0.160 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2017 | 48 | 0.150 |
Why?
|
| Virus Replication | 1 | 2022 | 607 | 0.150 |
Why?
|
| Immunotherapy | 4 | 2023 | 758 | 0.150 |
Why?
|
| Cancer Vaccines | 3 | 2005 | 188 | 0.140 |
Why?
|
| Female | 27 | 2026 | 70240 | 0.140 |
Why?
|
| Adenoviridae | 5 | 2023 | 581 | 0.140 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 177 | 0.140 |
Why?
|
| Adult | 16 | 2026 | 31012 | 0.130 |
Why?
|
| Middle Aged | 15 | 2026 | 28315 | 0.130 |
Why?
|
| Adolescent | 15 | 2025 | 20796 | 0.130 |
Why?
|
| DNA Virus Infections | 1 | 2017 | 22 | 0.130 |
Why?
|
| Bone Marrow Transplantation | 1 | 2000 | 589 | 0.130 |
Why?
|
| DNA Viruses | 1 | 2017 | 30 | 0.130 |
Why?
|
| Rhabdomyosarcoma | 1 | 2020 | 229 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2024 | 968 | 0.120 |
Why?
|
| Lymphocyte Depletion | 3 | 2024 | 124 | 0.120 |
Why?
|
| Young Adult | 9 | 2024 | 9979 | 0.120 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2016 | 29 | 0.120 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 143 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 688 | 0.120 |
Why?
|
| Combined Modality Therapy | 4 | 2021 | 1212 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 126 | 0.120 |
Why?
|
| CD28 Antigens | 2 | 2017 | 76 | 0.120 |
Why?
|
| Genes, Transgenic, Suicide | 2 | 2015 | 48 | 0.120 |
Why?
|
| CD40 Ligand | 2 | 2005 | 65 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2000 | 815 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2021 | 608 | 0.110 |
Why?
|
| Stem Cell Transplantation | 3 | 2020 | 224 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2017 | 372 | 0.100 |
Why?
|
| Aged | 9 | 2026 | 20822 | 0.100 |
Why?
|
| Transgenes | 1 | 2014 | 316 | 0.100 |
Why?
|
| Adenoviridae Infections | 1 | 2013 | 76 | 0.090 |
Why?
|
| Vidarabine | 2 | 2024 | 91 | 0.090 |
Why?
|
| Immunophenotyping | 4 | 2017 | 332 | 0.090 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 1991 | 19 | 0.090 |
Why?
|
| Chemokines, C | 2 | 2002 | 10 | 0.090 |
Why?
|
| Child, Preschool | 9 | 2025 | 15002 | 0.090 |
Why?
|
| Sialoglycoproteins | 2 | 2002 | 43 | 0.090 |
Why?
|
| Lymphokines | 2 | 2002 | 62 | 0.090 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2011 | 68 | 0.090 |
Why?
|
| Transplantation, Autologous | 3 | 2020 | 253 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 1 | 2013 | 221 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 508 | 0.080 |
Why?
|
| Genetic Vectors | 3 | 2022 | 892 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 1325 | 0.080 |
Why?
|
| Cyclophosphamide | 2 | 2024 | 425 | 0.080 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 470 | 0.080 |
Why?
|
| Remission Induction | 3 | 2020 | 306 | 0.080 |
Why?
|
| Imidazoles | 1 | 1991 | 219 | 0.080 |
Why?
|
| Organic Chemicals | 3 | 2015 | 58 | 0.080 |
Why?
|
| Cytomegalovirus | 3 | 2017 | 258 | 0.070 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 706 | 0.070 |
Why?
|
| Gene Transfer Techniques | 3 | 2011 | 344 | 0.070 |
Why?
|
| Cell Line | 3 | 2022 | 2554 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 1305 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2016 | 820 | 0.060 |
Why?
|
| Software | 1 | 1991 | 733 | 0.060 |
Why?
|
| Cytokines | 3 | 2023 | 1332 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 870 | 0.060 |
Why?
|
| Leukemia, B-Cell | 1 | 2005 | 25 | 0.060 |
Why?
|
| Transplantation Conditioning | 2 | 2017 | 327 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 2 | 2017 | 383 | 0.050 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 23 | 0.050 |
Why?
|
| Albumins | 1 | 2024 | 87 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2024 | 129 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2024 | 272 | 0.050 |
Why?
|
| Regenerative Medicine | 1 | 2023 | 37 | 0.050 |
Why?
|
| Industry | 1 | 2003 | 29 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2024 | 410 | 0.050 |
Why?
|
| Quality Control | 1 | 2003 | 116 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2024 | 306 | 0.050 |
Why?
|
| Biotechnology | 1 | 2003 | 59 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2003 | 136 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2023 | 271 | 0.050 |
Why?
|
| Genetic Engineering | 1 | 2023 | 161 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2024 | 5034 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2023 | 213 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2023 | 345 | 0.040 |
Why?
|
| Infant | 4 | 2025 | 13265 | 0.040 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2021 | 55 | 0.040 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 283 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 352 | 0.040 |
Why?
|
| Biological Products | 1 | 2003 | 143 | 0.040 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2020 | 17 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 68 | 0.040 |
Why?
|
| Allografts | 1 | 2021 | 220 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 5166 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2024 | 1241 | 0.040 |
Why?
|
| Glioma | 1 | 2024 | 495 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 3713 | 0.040 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 1800 | 0.040 |
Why?
|
| Epitopes | 1 | 2020 | 323 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2020 | 317 | 0.030 |
Why?
|
| Viral Matrix Proteins | 1 | 2018 | 108 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 75 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 1120 | 0.030 |
Why?
|
| Prognosis | 2 | 2021 | 4848 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2021 | 506 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2017 | 40 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 118 | 0.030 |
Why?
|
| Adenoviruses, Human | 1 | 2017 | 97 | 0.030 |
Why?
|
| Herpesvirus 6, Human | 1 | 2017 | 53 | 0.030 |
Why?
|
| BK Virus | 1 | 2017 | 58 | 0.030 |
Why?
|
| Biopsy | 1 | 2020 | 1240 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2017 | 112 | 0.030 |
Why?
|
| Genetic Markers | 1 | 1998 | 589 | 0.030 |
Why?
|
| Mice | 2 | 2023 | 18160 | 0.030 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 12 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 2057 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 235 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 174 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 784 | 0.030 |
Why?
|
| Aspergillus fumigatus | 1 | 2014 | 41 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2014 | 92 | 0.030 |
Why?
|
| Aspergillosis | 1 | 2014 | 44 | 0.030 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2015 | 215 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1604 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 121 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 517 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 61 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2024 | 6401 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 525 | 0.020 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 90 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2015 | 765 | 0.020 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 154 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 713 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1069 | 0.020 |
Why?
|
| Microcomputers | 1 | 1991 | 11 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 2015 | 275 | 0.020 |
Why?
|
| Animals | 2 | 2023 | 33660 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 1991 | 31 | 0.020 |
Why?
|
| Drug Incompatibility | 1 | 1991 | 1 | 0.020 |
Why?
|
| Solutions | 1 | 1991 | 50 | 0.020 |
Why?
|
| Drug Compounding | 1 | 1991 | 38 | 0.020 |
Why?
|
| Ondansetron | 1 | 1991 | 9 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 1991 | 49 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2014 | 285 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2005 | 501 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 2191 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 1991 | 138 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 1991 | 229 | 0.020 |
Why?
|
| Transduction, Genetic | 2 | 2002 | 276 | 0.020 |
Why?
|
| Time Factors | 2 | 2014 | 6165 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1991 | 409 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2002 | 975 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 1991 | 532 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 716 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 1482 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2011 | 630 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 2574 | 0.010 |
Why?
|
| B7-2 Antigen | 1 | 2005 | 16 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2005 | 37 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2005 | 71 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2005 | 95 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2005 | 229 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2005 | 303 | 0.010 |
Why?
|
| Apoptosis | 1 | 2011 | 1826 | 0.010 |
Why?
|
| Immune System | 1 | 2005 | 99 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 17538 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 409 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3740 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2005 | 373 | 0.010 |
Why?
|
| Texas | 1 | 1991 | 3655 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2002 | 28 | 0.010 |
Why?
|
| Panniculitis | 1 | 2002 | 19 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2002 | 136 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 2002 | 111 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2002 | 227 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 421 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2002 | 188 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2002 | 351 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 781 | 0.010 |
Why?
|
| Skin | 1 | 2002 | 538 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 2462 | 0.010 |
Why?
|
| Genes, Viral | 1 | 1998 | 155 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 237 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 195 | 0.010 |
Why?
|